Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Posterior Leukoencephalopathy Syndrome | 3 | 2017 | 44 | 0.330 |
Why?
|
| Multiple Myeloma | 4 | 2021 | 3050 | 0.210 |
Why?
|
| Lewy Body Disease | 1 | 2023 | 5 | 0.200 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 133 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 605 | 0.170 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 302 | 0.170 |
Why?
|
| Bone Diseases | 1 | 2021 | 94 | 0.160 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 331 | 0.150 |
Why?
|
| Spleen | 1 | 2019 | 170 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2018 | 58 | 0.140 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 173 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1025 | 0.140 |
Why?
|
| Root Cause Analysis | 1 | 2017 | 7 | 0.130 |
Why?
|
| Maxillary Sinusitis | 1 | 2017 | 10 | 0.130 |
Why?
|
| Tooth Diseases | 1 | 2017 | 8 | 0.130 |
Why?
|
| Brain | 2 | 2017 | 1321 | 0.130 |
Why?
|
| Immunocompetence | 1 | 2017 | 19 | 0.130 |
Why?
|
| Periodontal Diseases | 1 | 2017 | 12 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 400 | 0.130 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2017 | 28 | 0.130 |
Why?
|
| Thyroid Nodule | 1 | 2017 | 31 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 1536 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 123 | 0.130 |
Why?
|
| Adenoma | 1 | 2017 | 113 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 114 | 0.120 |
Why?
|
| Pinealoma | 1 | 2015 | 7 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 51 | 0.110 |
Why?
|
| Epilepsy | 1 | 2017 | 187 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 71 | 0.110 |
Why?
|
| Lithium Compounds | 1 | 2014 | 12 | 0.110 |
Why?
|
| Muscular Diseases | 1 | 2014 | 63 | 0.100 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2013 | 40 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 69 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1162 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1217 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 638 | 0.080 |
Why?
|
| Humans | 14 | 2023 | 52469 | 0.080 |
Why?
|
| Ileal Neoplasms | 1 | 2008 | 1 | 0.070 |
Why?
|
| Buttocks | 1 | 2008 | 8 | 0.070 |
Why?
|
| Jejunal Neoplasms | 1 | 2008 | 4 | 0.070 |
Why?
|
| Leiomyosarcoma | 1 | 2008 | 22 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 2113 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2008 | 115 | 0.070 |
Why?
|
| Male | 9 | 2019 | 26794 | 0.060 |
Why?
|
| Neurosurgical Procedures | 2 | 2018 | 134 | 0.060 |
Why?
|
| Middle Aged | 6 | 2018 | 13084 | 0.060 |
Why?
|
| Female | 7 | 2021 | 28192 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2018 | 6643 | 0.060 |
Why?
|
| Neoplasms | 1 | 2014 | 1302 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2023 | 52 | 0.050 |
Why?
|
| Dopamine | 1 | 2023 | 169 | 0.050 |
Why?
|
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.040 |
Why?
|
| Adult | 4 | 2017 | 14151 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 133 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2021 | 363 | 0.040 |
Why?
|
| Aged | 3 | 2019 | 10193 | 0.040 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2018 | 11 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2018 | 15 | 0.040 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2018 | 25 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 218 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2018 | 68 | 0.040 |
Why?
|
| Maxilla | 1 | 2017 | 14 | 0.030 |
Why?
|
| Facial Bones | 1 | 2017 | 18 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2021 | 494 | 0.030 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2017 | 35 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 487 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2017 | 78 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2017 | 94 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 949 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 387 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2017 | 303 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2015 | 80 | 0.030 |
Why?
|
| Arkansas | 1 | 2021 | 2024 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 26 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2015 | 128 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2013 | 21 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1216 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2288 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 47 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 638 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2013 | 241 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 765 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 284 | 0.020 |
Why?
|
| Thalidomide | 1 | 2013 | 378 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2013 | 439 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 715 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 2670 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3413 | 0.020 |
Why?
|
| Intussusception | 1 | 2008 | 9 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 2989 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4326 | 0.020 |
Why?
|